Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 80
- Locations
- 3
- Primary Endpoint
- Utility of B regulatory cells as a biomarker of AIT treatment sucess
Study Overview
Brief Summary
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is;
1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen.
Patients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.
Detailed Description
Allergen immunotherapy (AIT) is a disease-modifying treatment for allergic disease which promotes immune system tolerance, i.e. reduces clinical manifestations of allergy and is the only known effective treatment to prevent anaphylaxis in patients who have previously had serious reactions to insect venoms. AIT induces a variety of immune system changes to facilitate this process, one mechanism of which is the production of a population of white blood cells called B-regulatory cells (BREGs). These cells release a chemical called interleukin-10 (IL-10) which inhibits (controls) the allergic immune response. The success of AIT is difficult to establish/monitor during treatment. Often treatment success can only be established at the end of a long treatment period (typically 3 years) and currently clinicians rely on patient symptoms upon re-exposure to further allergen post-treatment. Therefore there is a requirement to identify a marker (biomarker) which can be tested for during treatment to help clinicians establish at an earlier time, if the AIT is showing success or if a change to treatment is required. This research will measure the BREG and IL-10 production in patients before and at multiple points during AIT, to establish if there is a relationship between the BREG/IL-10 concentration and the success or failure of AIT in controlling patient symptoms of allergy. The hope is that BREG measurement could be used in the future as a biomarker for AIT efficacy, and therefore provide evidence of AIT success sooner than current protocols, or establishing failure of AIT and therefore expediting a change in treatment. The latter will likely result in saving time in pursuing a treatment which is not working, but also for understanding when the treatment has already reached optimal effectiveness and can be stopped.
Overall Aim:
To develop a flow cytometry assay for the identification and quantitation of human B regulatory cells to allow evaluation of their potential role as a treatment efficacy biomarker in allergen-specific immunotherapy.
Primary Objectives:
- Identification of a biomarker that defines success of allergen immunotherapy
- Development of a novel flow cytometry assay to detect and quantify B-regulatory cells in whole blood/peripheral blood mononuclear cell (PBMC) isolate
- Determine the reference intervals for BREG cell quantitation in the test and control groups using conventional parametric or non-parametric measures, depending on the characteristics of the data obtained
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Control cohort - Participants with:
- •No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms
- •Negative serological testing for specific IgE to pollens, house dust mite and insect venoms
- •Patients aged 18 years or older
- •Test cohort:
- •Participants over the age of 18 years
- •Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms
Exclusion Criteria
- •Patients under the age of 18 years
- •Samples from patients with IgE-mediated allergic disease, treated or untreated, specific to allergens other than pollens, house dust mite and insect venom
- •Participants who are pregnant
- •Participants who cannot adequately understand verbal and / or written explanations given in English
Arms & Interventions
Control Cohort
- Participants routinely attending the Immunology and Allergy Clinical at Hull University Teaching Hospitals
- Participants over the age of 18 years
- Participants with no clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms, negative serological testing for specific IgE to pollens, house dust mite and insect venoms)
Intervention: Venepuncture (Diagnostic Test)
Test Cohort
- Participants routinely attending the Immunology and Allergy Clinical at Hull University Teaching Hospitals
- Participants over the age of 18 years
- Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms
- Participants who are eligible to commence allergen immunotherapy (AIT). AIT will comprise;
- Sublingual immunotherapy (SLIT) Grazax for grass pollen allergy or Acarizax for house dust mite allergy
- Subcutaneous immunotherapy (SCIT) Venom immunotherapy involving subcutaneous injections against bee or wasp venoms (as per schedule following conventional or modified rush protocols)
AIT eligibility decided upon through combination of clinical assessment, multi-disciplinary team (MDT) meeting discussion and BSACI guidance.
Intervention: Allergen Specific Immunotherapy (Drug)
Test Cohort
- Participants routinely attending the Immunology and Allergy Clinical at Hull University Teaching Hospitals
- Participants over the age of 18 years
- Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms
- Participants who are eligible to commence allergen immunotherapy (AIT). AIT will comprise;
- Sublingual immunotherapy (SLIT) Grazax for grass pollen allergy or Acarizax for house dust mite allergy
- Subcutaneous immunotherapy (SCIT) Venom immunotherapy involving subcutaneous injections against bee or wasp venoms (as per schedule following conventional or modified rush protocols)
AIT eligibility decided upon through combination of clinical assessment, multi-disciplinary team (MDT) meeting discussion and BSACI guidance.
Intervention: Venepuncture (Diagnostic Test)
Outcomes
Primary Outcomes
Utility of B regulatory cells as a biomarker of AIT treatment sucess
Time Frame: From enrolment to 1 year post commencing allergen-specific immunotherapy treatment
To assess whether an increase in regulatory B cell concentration is a useful biomarker to indicate AIT treatment success and specific allergen de-sensitisation.
Secondary Outcomes
- Develop a flow cytometry laboratory assay for the detection of B regulatory cells(From study commencement (planned May 2025) to end of study data collection (planned May 2027))